MultiOmic Health
MultiOmic Health is an AI-enabled drug discovery company dedicated to developing novel therapeutics and diagnostics for serious complications of metabolic dysfunction, which is the world's largest healthcare burden. Using a unique combination of deep longitudinal patient datasets, AI-enabled data science, and experimental biology, they identify patient subpopulations with distinct molecular disease drivers to originate and pursue their own therapeutic R&D programs, including drug discovery pipelines and companion diagnostics. Their mission is to transform patient outcomes through precision medicine for metabolic syndrome-related conditions. The company is actively collaborating with partners such as Mesh Bio to leverage AI for developing precision medicines and diagnostics for chronic metabolic diseases.
Industries
Nr. of Employees
small (1-50)
MultiOmic Health
Epworth House, 25 City Road, Shoreditch, London, EC1Y 1AA
Services
Analysis of bespoke longitudinal cohorts to identify patient endotypes and develop predictive biomarker models for disease trajectory and treatment response.
Using integrated multi-omics, machine learning and systems-biology modelling to identify and prioritise novel drug targets and therapeutic concepts, including repositioning and combination strategies.
Targeted in vitro and ex vivo experiments to validate computational hypotheses and support selection of preclinical development candidates and IND-enabling studies.
Design and commissioning of laboratory services to implement stratifying biomarker assays as laboratory-developed tests or IVDs to support clinical trials and clinical decision-making.
Deployment of an integrated Patient-to-Data and Data-to-Therapeutics platform through value-sharing partnerships, licensing arrangements and co-funded discovery programs.
Analysis and modelling to identify existing NMEs or drug combinations that may be effective in specific patient endotypes for repurposing efforts.
Analysis of bespoke longitudinal cohorts to identify patient endotypes and develop predictive biomarker models for disease trajectory and treatment response.
Using integrated multi-omics, machine learning and systems-biology modelling to identify and prioritise novel drug targets and therapeutic concepts, including repositioning and combination strategies.
Targeted in vitro and ex vivo experiments to validate computational hypotheses and support selection of preclinical development candidates and IND-enabling studies.
Design and commissioning of laboratory services to implement stratifying biomarker assays as laboratory-developed tests or IVDs to support clinical trials and clinical decision-making.
Deployment of an integrated Patient-to-Data and Data-to-Therapeutics platform through value-sharing partnerships, licensing arrangements and co-funded discovery programs.
Analysis and modelling to identify existing NMEs or drug combinations that may be effective in specific patient endotypes for repurposing efforts.
Expertise Areas
- Multi-omics data generation and integration
- Longitudinal cohort curation and de-identified clinical data management
- AI/ML-driven biomarker discovery and patient stratification
- Systems biology modelling and simulation
Key Technologies
- Next-generation sequencing
- Epigenomic profiling
- Transcriptomics
- Mass-spectrometry proteomics
News & Updates
The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform and innovative renal therapeutic programs.
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions.
Robert Thong, CEO, discussed advancing precision medicine for metabolic-syndrome-related conditions at the LSX Investival Showcase in London.
MultiOmic Health identified novel patient endotypes and proprietary biomarkers for stratifying diabetic kidney disease patients, enabling precise segmentation and potential for targeted therapies.
Robert Thong will share insights into addressing cardiorenal complications associated with diabetes at the conference in Spain.
The article discusses how recent trials can inform the use of molecular-level disease drivers in precision nephrology.
The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform and innovative renal therapeutic programs.
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions.
Robert Thong, CEO, discussed advancing precision medicine for metabolic-syndrome-related conditions at the LSX Investival Showcase in London.
MultiOmic Health identified novel patient endotypes and proprietary biomarkers for stratifying diabetic kidney disease patients, enabling precise segmentation and potential for targeted therapies.
Robert Thong will share insights into addressing cardiorenal complications associated with diabetes at the conference in Spain.
The article discusses how recent trials can inform the use of molecular-level disease drivers in precision nephrology.